Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Status: Recruiting
Phase:
Diagnosis: Lung Cancer
NCT ID: NCT01348126 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-357

 

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.

 

Conducting Institutions:
Dana-Farber Cancer Institute

Overall PI:
Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Kelly Masone, 617-632-3383, kmasone@partners.org

Eligibility Criteria

Inclusion Criteria: - confirmed diagnosis of NSCLC - Stage IIIB or IV NSCLC - ECOG Performance Status 0 or 1 - Prior therapy defined as 1 prior systemic therapy for advanced disease - measurable disease - Radiologic evidence of disease progression following most recent prior treatment. - Adequate hematologic, hepatic, renal function Exclusion Criteria: - Active or untreated CNS metastases - Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin - Serious cardiac illness or medical conditions - Pregnant or lactating women - Uncontrolled intercurrent illness
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms